An unprecedented surge in innovation in the life sciences and healthcare sectors means that reputations and communications need to be stronger than ever. Whether you’re a large pharmaceutical, a mid-sized biotech or a small IP-based operation, strategic partnerships and advice based on broad sector-experience are critical, as you navigate complex relationships and grow your business.
How Buchanan can help Buchanan has worked closely with the healthcare sector since the early 1990s, when we advised on the first wave of UK biotechnology IPOs. In total we have advised on more than 35 healthcare IPOs, ranging from loss-making biotech companies to cash generative businesses in pharmaceutical services, IT and medical devices. Our experience spans multiple markets worldwide, including AIM, the LSE main market and Nasdaq.